- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01790594
Optimisation de l'utilisation de NULOJIX® pour minimiser l'exposition aux CNI lors d'une greffe simultanée de pancréas et de rein
Optimisation de l'utilisation de NULOJIX® (Belatacept) comme moyen de minimiser l'exposition aux CNI lors d'une greffe simultanée de pancréas et de rein (CTOT-15)
The purpose of this study is to find out if the drug NULOJIX® (belatacept) will minimize the amount of other anti-rejection medications necessary and thereby reduce the long-term side effects caused by the other medications. The researchers also want to learn more about the safety of this treatment and long term health of transplanted pancreases and kidneys.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Transplant recipients have to take anti-rejection medications to prevent their immune systems (the body's natural defense system against illness) from rejecting their new organs. Most patients who receive a transplanted organ must take these anti-rejection medications for the rest of their lives, or for as long as the transplanted organ continues to work. Taking standard anti-rejection medications for a long time can cause serious side effects, including pancreas and kidney damage. There would be a benefit to finding new anti-rejection medications that work just as well, but could lessen the amount of anti-rejection medications that are taken long term.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- University of Alabama at Birmingham
-
-
California
-
San Francisco, California, États-Unis, 94143-0780
- University of California San Francisco Medical Center
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Emory University
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University Hospital
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53792
- University of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Ability to understand and provide written informed consent;
- Candidate for a primary simultaneous kidney and pancreas allograft with random c-peptide <0.3 ng/mL;
- No known contraindications to study therapy using NULOJIX® (belatacept);
- Female subjects of childbearing potential must have a negative pregnancy test upon study entry;
- Female and male participants with reproductive potential must agree to use FDA approved methods of birth control during participation in the study and for 4 months following study completion;
- No donor specific antibodies prior to transplant that are considered to be of clinical significance by the site investigator;
- Negative crossmatch, actual or virtual, or a Panel Reactive Antibodies (PRA) of 0% on historic and admission sera, as determined by each participating study center;
- A documented negative Tuberculosis (TB) test within the 12 months prior to transplant. If documentation is not present at the time of transplantation, and the subject does not have any risk factors for TB, a TB-specific interferon gamma release assay (IGRA) may be performed.
Exclusion Criteria:
- Need for multi-organ transplantation other than a kidney and pancreas;
- Recipient of previous organ transplant;
- Epstein-Barr Virus (EBV) sero-negative recipients or recipients whose EBV serostatus is unknown prior to the time of transplantation;
- Individuals infected by the hepatitis B or C viruses or HIV;
- Individuals who have required treatment with systemic prednisone or other immunosuppressive drugs within 1 year prior to transplant;
- Individuals previously treated with NULOJIX® (belatacept);
- Any condition that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements;
- Use of investigational drugs within 4 weeks of enrollment;
- Known hypersensitivity to mycophenolate mofetil (MMF)or any of the drug's components;
- Administration of live attenuated vaccine(s) within 8 weeks of enrollment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Immunosuppression without Belatacept
|
Autres noms:
Autres noms:
There may be an opportunity to withdraw tacrolimus at week 40
Autres noms:
Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
Autres noms:
|
|
Expérimental: Immunosuppression Including Belatacept
|
Autres noms:
Autres noms:
There may be an opportunity to withdraw tacrolimus at week 40
Autres noms:
Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
Autres noms:
The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean Estimated Glomerular Filtration Rate (eGFR) Calculated for Each Treatment Group Using the CKD-EPI Equation at Wk 52 Post-Transplant
Délai: Week 52 Post-Transplant
|
eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI):
|
Week 52 Post-Transplant
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Count of Participants With eGFR < 60 mL/Min/1.73 m^2 Measured by CKD-EPI at Wk 52 Post-Transplant
Délai: Week 52 Post-Transplant
|
eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI):
|
Week 52 Post-Transplant
|
|
Count of Participants by CKD Stage at Wk 52 Post-Transplant
Délai: Week 52 Post-Transplant
|
The stages of Chronic Kidney Disease are defined using the participant's GFR value:
Stages 3A and 3B indicate moderately reduced kidney function.* |
Week 52 Post-Transplant
|
|
Count of Participants With Defined CKD Stage 4 or 5 at Wk 52 Post-Transplant
Délai: Week 52 Post-Transplant
|
The stages of Chronic Kidney Disease (CKD) are defined using the participant's GFR value:
Stages 3A abd 3B indicate moderately reduced kidney function.* |
Week 52 Post-Transplant
|
|
Mean Calculated eGFR Using MDRD 4 Variable Model at Wk 52 Post-Transplant
Délai: Week 52 Post-Transplant
|
The estimated Glomerular Filtration Rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation (MDRD):
|
Week 52 Post-Transplant
|
|
The Slope of eGFR by CKD-EPI Over Time Based on Serum Creatinine Post-Transplant
Délai: Day 28 through Week 52 Post-Transplant
|
The estimated Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI):
An estimate of the slope, or change over time, in eGFR was produced using standard statistical linear modeling procedures. The estimate was then re-scaled so that it could be interpreted as a change in eGFR per month. Positive numbers indicate increasing kidney function. Larger numbers indicate greater change in kidney function. |
Day 28 through Week 52 Post-Transplant
|
|
Count of Participants With Successful Discontinuation of Tacrolimus in Recipients Randomized to the Investigational Arm
Délai: Week 40 through week 48 Post-Transplant
|
Participants achieved successful discontinuation if they were able to discontinue (e.g., off tacrolimus therapy completely) over a 4-8 weeks after tacrolimus withdrawal was initiated at week 40. |
Week 40 through week 48 Post-Transplant
|
|
Count of Participants With Delayed Graft Function at Wk 52 Post-Transplant
Délai: Transplant through Week 52 Post-Transplant
|
Delayed grafted function is defined as dialysis in the first week on one or more occasions for any indication other than the treatment of acute hyperkalemia in the setting of otherwise acceptable renal function. |
Transplant through Week 52 Post-Transplant
|
|
Count of Participants With Full Pancreatic Graft Function (Insulin Independent) at Wk 52 Post-Transplant
Délai: Week 52 Post-Transplant
|
Participants with full pancreatic graft functions are defined as those that no longer require exogenous insulin therapy. |
Week 52 Post-Transplant
|
|
Count of Participants With Evidence of Partial Pancreatic Graft Function at Week 52 Post-Transplant
Délai: Week 52 Post-Transplant
|
C-peptide is a measure of pancreatic function. The definition of partial pancreatic graft function: a fasting C-peptide levels >0.3ng.mL (0.1nmol.L) plus the participant's continued requirement for exogenous insulin or oral hypoglycemic agent(s). |
Week 52 Post-Transplant
|
|
Count of Participants With Evidence of Pancreatic Loss at Week 52 Post-Transplant
Délai: Week 52 Post-Transplant
|
C-peptide is a measure of pancreatic function. The definition of pancreatic loss: a C-peptide value of <0.3 ng/mL. |
Week 52 Post-Transplant
|
|
HbA1c at Baseline (Pre-Transplant) Through Wk 52 Post-Transplant
Délai: Baseline (Pre-Transplant) and Days 28, 84, and Weeks 28, 36, and 52
|
Hemoglobin A1c (HbA1c) measures the average blood glucose levels over 8-12 weeks, thus acting as a useful long-term gauge of blood glucose control:
|
Baseline (Pre-Transplant) and Days 28, 84, and Weeks 28, 36, and 52
|
|
Fasting Blood Sugar (FBS) From Baseline (Pre-Transplant) Through Wk 52 Post-Transplant
Délai: Baseline (Pre-Transplant) and Days 28, 84, and Weeks 28, 36, and 52
|
Fasting blood sugar (e.g., glucose) test is used to help diagnose diabetes, prediabetes, and gestational diabetes. Reference fasting blood sugar (glucose) values:
|
Baseline (Pre-Transplant) and Days 28, 84, and Weeks 28, 36, and 52
|
|
Standardized Blood Pressure Measurement From Baseline (Pre-Transplant) Through Wk 52 Post-Transplant
Délai: Baseline (Pre-Transplant) and Days 28, 84, and Weeks 28, 36, and 52
|
A blood pressure measurement consists of two numbers: the systolic and diastolic pressures. Systolic pressure measures the pressure in blood vessels when the heart beats. Diastolic pressure measures the pressure in blood vessels between beats of the heart.
|
Baseline (Pre-Transplant) and Days 28, 84, and Weeks 28, 36, and 52
|
|
Count of Participants With Use of Anti-hypertensive Medication From Baseline (Pre-Transplant) Through Wk 52 Post-Transplant
Délai: Baseline (Pre-Transplant) and Days 28, 84, and Weeks 28, 36, and 52
|
Anti-hypertensive medications are a class of drugs that are used to treat hypertension. The medications seek to prevent the complications of high blood pressure, such as stoke and myocardial infarction. |
Baseline (Pre-Transplant) and Days 28, 84, and Weeks 28, 36, and 52
|
|
Fasting Lipid Profile at Baseline (Pre-Transplant)
Délai: Baseline (Pre-Transplant)
|
A fasting lipid profiles measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels. These measurements are used in assessing one's risk of cardiovascular disease. Target ranges for each of these measures are provided:
|
Baseline (Pre-Transplant)
|
|
Fasting Lipid Profile at Wk 28 Post-Transplant
Délai: Week 28 Post-Transplant
|
A fasting lipid profiles measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels. These measurements are used in assessing one's risk of cardiovascular disease. Target ranges for each of these measures are provided:
|
Week 28 Post-Transplant
|
|
Lipid Profile at Wk 52 Post-Transplant
Délai: Week 52 Post-Transplant
|
A fasting lipid profiles measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels. These measurements are used in assessing one's risk of cardiovascular disease. Target ranges for each of these measures are provided:
|
Week 52 Post-Transplant
|
|
Count of Participants With Use of Lipid Lowering Medications at Baseline, Wk 28 and Wk 52 Post-Transplant
Délai: Baseline (Pre-Transplant), Week 28, and Week 52
|
Lipid lowering medications are used in the treatment of high levels of fats (lipids), such as cholesterol in blood |
Baseline (Pre-Transplant), Week 28, and Week 52
|
|
Count of Participants With Acute Rejection (AR) of Kidney or Pancreatic Transplant During the First 52 Wks Post-Transplant
Délai: Transplant through Week 52
|
Biopsy-proven acute rejection (AR) of the kidney (renal) or pancreas during the first 52 weeks post-transplant. AR grading using standard Banff* criteria. For both kidney and pancreas, AR is defined as a grade ≥1.
|
Transplant through Week 52
|
|
Severity Grade of First Biopsy-Proven Acute Rejection (AR) During the First 52 Weeks Post-Transplant
Délai: Transplant through Week 52
|
AR grading using standard Banff* criteria. For both kidney and pancreas, AR is defined as a grade ≥1.
|
Transplant through Week 52
|
|
Count of Participants With Biopsy-Proven Humoral Rejection During the First 52 Weeks Post-Transplant
Délai: Transplant through Week 52
|
Humoral rejection (i.e., antibody mediated rejection) of:
|
Transplant through Week 52
|
|
Count of Participants With De Novo Anti-Donor Antibodies or Anti-Human Leukocyte Antigen (HLA) Antibodies During the First 52 Weeks Post-Transplant
Délai: Transplant through Week 52
|
The de novo development of donor-specific antibody (DSA) is associated with an increased risk of graft rejection. The presence of anti-Histocompatibility Antigen (HLA) antibodies (alloantibodies) is associated with increased risk of acute and chronic injury to the transplant allograft. |
Transplant through Week 52
|
|
Type of Treatment(s) Participants Received for Biopsy-Proven Renal Allograft Rejection During the First 52 Weeks Post-Transplant
Délai: Transplant through Week 52
|
Participants are stratified by kidney biopsy results/treatment received. In the event of a for cause renal (kidney) biopsy: -The diagnosis of acute cellular rejection (ACR) using the Banff 2007 renal allograft pathology criteria. These criteria for renal allograft biopsies is an international histopathological classification standard. ACR is defined by a renal biopsy demonstrating a Banff 2007 classification of Grade IA or greater, with higher scores indicating more severe rejection. (Ref: Solez K, Colvin RB et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008 8(4): 753-60). Acronyms and abbreviations:
|
Transplant through Week 52
|
|
Type of Treatment(s) Participants Received for Biopsy-Proven Pancreatic Allograft Rejection During the First 52 Weeks Post-Transplant
Délai: Transplant through Week 52
|
Participants are stratified by kidney biopsy results/treatment received. Upon having a for-cause biopsy performed, persons often receive treatment for rejection based on the biopsy results, which may or may not reveal signs of rejection. Details of biopsy findings and corresponding treatment are provided for each instance of treatment for rejection. Results summary format: biopsy results; treatment. Acronyms and abbreviations:
|
Transplant through Week 52
|
|
Count of Participants With Event of Death, Graft Loss, or Undetectable C-peptide
Délai: Transplant through Week 52 Post-Transplant
|
This measure counts death, graft loss, or undetectable C-peptide value (e.g., C-peptide <0.3 ng/mL) occurring at any point post-transplant and independent of each other.
|
Transplant through Week 52 Post-Transplant
|
|
Count of Participants With the Occurrence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: From Enrollment (Pre-Transplant) to Week 52 Post-Transplant
|
Adverse events were collected systematically. Counts of all participants who experienced at least one adverse event (AEs, SAEs) by assigned treatment group. Refer to the Serious Adverse Events and Other Adverse Events tables for more detail. |
From Enrollment (Pre-Transplant) to Week 52 Post-Transplant
|
|
Count of Participants With an Infectious Disease Serious Adverse Event(s) Requiring Hospitalization or Systemic Therapy
Délai: Transplant through Week 52 Post-Transplant
|
Infections were required to be reported as a serious adverse event if they required either inpatient hospitalization or prolongation of a current hospitalization. Displayed are counts of all participants who experienced infection(s) as an adverse event, by treatment group. |
Transplant through Week 52 Post-Transplant
|
|
Count of Participant Diagnosed With BK Polyoma Virus (BKV) and Cytomegalovirus (CMV) Viremia As Adverse Events
Délai: Transplant through Week 52 Post-Transplant
|
Viral infections following renal transplantation is a significant source of recipient morbidity and mortality, and a significant cause of allograft dysfunction and loss. Specific viruses were monitored during this study using participant blood samples. Displayed are counts of participants who experienced BKV and CMV viremia as adverse events, diagnosed by test results from the local clinical pathology laboratory. |
Transplant through Week 52 Post-Transplant
|
|
Count of Participants Diagnosed With Epstein-Barr Virus (EBV) Infection as an Adverse Event
Délai: Transplant through Week 52 Post-Transplant
|
Viral infections following renal transplantation is a significant source of recipient morbidity and mortality, and a significant cause of allograft dysfunction and loss. Specific viruses were monitored during this study using participant blood samples. Displayed are counts of all participants diagnosed with EBV infection as an adverse event by EBV test(s), diagnosed by test results from the local clinical pathology laboratory. |
Transplant through Week 52 Post-Transplant
|
|
Count of Participants Diagnosed With Malignancy as an Adverse Event
Délai: Transplant through Week 52 Post-Transplant
|
An increased risk/incidence of malignancy is a recognized complication of immunosuppression in recipients of organ transplants. In Phase 3 clinical trials, overall malignancy rates were similar across all treatment groups, with the exception of posttransplant lymphoproliferative disease (PTLD).Displayed are counts of all participants who experienced malignancy reported as an adverse event. |
Transplant through Week 52 Post-Transplant
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chercheur principal: Kenneth Newell, MD, PhD, Emory University
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Immunoconjugués
- Acides aminés, peptides et protéines
- Protéines
- Produits chimiques organiques
- Acides gras
- Lipides
- Acides, acyclique
- Acides carboxyliques
- Composés polycycliques
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Prégnades
- Grossesse
- Stéroïdes
- Composés à anneau fusionné
- Macrolides
- Lactones
- Grossissement
- Produits biologiques
- Mélanges complexes
- Caproates
- Prednisolone
- Sérums immunitaires
- Abatacept
- Acide mycophénolique
- Méthylprednisolone
- Tacrolimus
- Sérum antilymphocytaire
- thymoglobuline
Autres numéros d'identification d'étude
- DAIT CTOT-15
- U01AI084150 (Subvention/contrat des NIH des États-Unis)
- NIAID CRMS ID#: 20117 (Autre identifiant: DAIT NIAID)
- SDY1433 (Autre identifiant: ImmPort)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Data is available in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
Délai de partage IPD
On average, data is available within 24 months after database lock for a trial.
Critères d'accès au partage IPD
Open access.
Study's:
- Accession ID is SDY1433, and
- Digital Object Identifier (DOI) is : 10.21430/M3CEH2A7ZF
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .